Clinical Trials Logo

Filter by:
NCT ID: NCT05606107 Recruiting - Clinical trials for Rheumatoid Arthritis

To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks

Start date: May 20, 2022
Phase: Phase 4
Study type: Interventional

Glucocorticoids are effective in the treatment of rheumatoid arthritis, but long-term use of glucocorticoids has many side effects. Tofacitinib is a new small-molecule drug targeting JAK, which has been found to act quickly. The aim of this clinical trial was to investigate the efficacy and safety of tofacitinib and low-dose glucocorticoids in inducing remission in patients with rheumatoid arthritis with moderate to high disease activity.

NCT ID: NCT05606094 Completed - Gastric Cancer Clinical Trials

Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Start date: March 9, 2023
Phase:
Study type: Observational

This study will be conducted to understand real-world treatment patterns, participant characteristics (demographic and clinico-pathological characteristics), clinical outcomes and safety of different treatment regimens, and healthcare resource utilization in East Asia for HER2-positive locally advanced or metastatic gastric or gastroesophageal adenocarcinoma (de novo advanced disease, relapsed/progressed) in a real-world setting.

NCT ID: NCT05605665 Recruiting - Sjögren's Syndrome Clinical Trials

Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome

Start date: November 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this paper is to analysis of therapeutic effect and immunological mechanism of low-dose IL-2 combined with rapamycin in the treatment of Sjogren's syndrome

NCT ID: NCT05605613 Recruiting - NSCLC Clinical Trials

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

Start date: October 29, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized controlled trial to determine the efficacy and safety of PD-1 Antibody in addition to Bronchial Arterial Chemoembolization in stage III-Ⅳ NSCLC patients who failed, refused or ineligible to receive standard treatments.

NCT ID: NCT05605418 Not yet recruiting - Hypertension Clinical Trials

Study of a Comprehensive Intelligent Hypertension managEment SyStem

CHESS
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

This cluster randomized controlled trial aims to evaluate the efficacy of a comprehensive intelligent hypertension management system (CHESS) in blood pressure lowering in primary health care (PHC) settings of China.

NCT ID: NCT05605314 Recruiting - Dry Eye Clinical Trials

Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye

pSS
Start date: January 1, 2021
Phase:
Study type: Observational

Primary Sjögren's syndrome is a chronic autoimmune disease that primarily involves exocrine glands, most commonly manifested in dry eye, dry mouth, and in other systems of the body.

NCT ID: NCT05605197 Recruiting - Pancreatic Cancer Clinical Trials

U87 CART in Treatment of Advanced Solid Tumor

Start date: October 19, 2022
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, phase 1 study to evaluate the safety and efficacy of U87 CART in treating advanced solid tumor .

NCT ID: NCT05605145 Recruiting - Diagnosis Clinical Trials

PCP in Immunocompromised Population in Southern China

PCP
Start date: May 12, 2021
Phase:
Study type: Observational

To evaluate the sensitivity and specificity of the combined detection system for the diagnosis of pneumocystis infection in immunocompromised population in Southern China.

NCT ID: NCT05605002 Recruiting - Clinical trials for Major Depressive Disorder

Efficacy and Safety of Intradermal Acupuncture for Major Depressive Disorder

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is a common mental illness that severely affects the health and quality of life of patients. Treatment with acupuncture alone or a combination of appropriate adjuncts has been reported to be significantly effective in reducing the severity of MDD, relieving patients' somatic symptoms and improving sleep. This study will focus on the intradermal acupuncture, which is more convenient, gentler and has longer lasting effects. The aim is to study the efficacy and safety of intradermal acupuncture for MDD, and to preliminarily explore the central nervous mechanisms by which it exerts its therapeutic effects.

NCT ID: NCT05604937 Recruiting - Clinical trials for Cervicogenic Dizziness

Safety and Efficacy of Shi's Traumatology Osteopathic Manipulative Treatment for Cervicogenic Dizziness

SESTOMTCD
Start date: February 2, 2023
Phase: N/A
Study type: Interventional

This is a randomized, controlled, multi-center clinical trail to objectively evaluate safety and efficacy of shi's traumatology Osteopathic manipulative treatment for cervicogenic dizziness. Multi-center study is planned to be carried out in 4 medical institutions in Shanghai, including Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Yueyang traditional chinese and western medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Baoshan traditional chinese and western medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and Shanghai General Hospital. Randomly Assigned 106 patients (18 < ages <65 ) who meet the diagnostic criteria of cervicogenic dizziness to the treatment group and the control group by a ratio of 1:1, using betahistine mesylate tablets as positive control. Observe and compare the variations of Dizziness Handicap Inventory (DHI) from baseline in two groups after 2 weeks treatment, using Dizziness Handicap Inventory (DHI) as the main efficacy index. After the end of treatment, performing 4weeks follow-up, focus to compare the recurrence rate of vertigo symptoms in the period of 4weeks follow-up after 2 weeks treatment. The safety indexes will be observed and compared, including vital sign, physical examination and adverse event, in the trail. The electronic case Report Form (eCRF) will be used to collect and manage the study data. The data of the primary efficacy index, DHI, patient's vertigo condition report, both use electronic patient-reported outcome (e-PRO) to collect. To ensure quality of study, this trail intends to set safeguard measures for clinical trail including setting Clinical Research Associate (CRA) to monitor study quality, evaluating efficacy by the third person, training manual therapy physicians, make access and regular and irregular assessment consistent.